Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 242-354-0 | CAS number: 18472-51-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Toxicokinetic studies have been performed for the oral and the dermal route of application in several species including humans. Studies with other Chlorhexidine salts like diacetate were used (see read across statement under chapter 13.2 Other assessment reports.)
Oral Route
Independent from the dose applied and the species (including rats, dogs, marmosets, rhesus monkeys and humans), about 0.2 - 1.3 % of the dose are excreted with via urine. For mice conflicting results have been reported: One study gave 3.7 - 7.2 % of the dose, while another study gave only 0.46 - 1.25 %. The majority of the applied dose (in most studies > 90 %) is recovered from faeces, which is considered to represent unabsorbed material. This is confirmed by data from a study with rats, were only 0.2 % of the orally applied dose was found in bile. In studies with dogs and rats investigating the distribution of chlorhexidine digluconate, chlorhexidine was also detected in the liver.
Based on the observations in rats, where excretion via the urine and biliary excretion have been quantified, possibly equal amounts are excreted in the urine and bile.
Overall, the absorption in different species therefore may account for up to 2.6 % of the dose, if the one study with mice with higher excretion via urine is not taken into consideration.
Excretion of 14C-radioactivity (as % of dose ± SE) following oral
administration of
14C‑chlorhexidine digluconate to different species
Species |
Dose* (mg/kg b.w.) |
14C-Label1 |
Urine |
Faeces |
Days |
Rat4 |
5 |
R |
0.4 |
99.5 |
7 |
Rat |
4 |
|
|
Bile |
3 |
Mouse4 |
27 |
R |
7.2 |
91.9 |
7 |
Mouse |
25 |
R |
0.52 |
70.3 |
7 |
Dog4 |
5 |
R |
0.8 |
102.0 |
7 |
Marmoset4 |
7.3 |
R |
1.3 |
89.4 |
5 |
Rhesus monkey4 |
5.5 |
R |
1.2 |
102.6 |
7 |
Human |
0.07 |
R |
0.3 |
81.9 |
6 |
*:
reported as chlorhexidine base; n.r. not reported
1: R: ring-, C: chain-labelled
2: male, after 6 months daily dosing
3: female, after 6 months daily dosing
4: no. of animals not reported but probably n=1 for each data set.
Distribution
Data from an autoradiographic study in female mice (distribution of chlorhexidine from 14C-labelled chlorhexidine digluconate and diacetate) showed that the radiolabelled chlorhexidine (or a metabolite containing the 14C-activity) had a high affinity to the epithelia of the gastrointestinal and the respiratory tract and also could be detected in the liver and in the kidney.
The distribution of chlorhexidine was also measured after repeated (chronic) oral exposure for up to one year in dogs and two years in rats. Limited data are also available for mice. The concentration of chlorhexidine in blood and various organs of rats was dose- and time-dependent and highest concentrations in blood were reached after one year and generally did not increase further or declined during the second half of the study. The highest concentrations were found in kidneys and in mesenteric lymph nodes, while concentration in other organs were at least one order of magnitude lower.
In dogs, detectable levels of chlorhexidine in blood were only found in the highest dose group. Blood chlorhexidine increased with increasing exposure time and the observed decline from 6 – 9 months can be explained by the dose reduction after 28 weeks (40à25 mg/kg bw/d). Highest concentrations were found in liver, followed by kidney and mesenteric lymph nodes, while other organs contained much lower concentrations.
The data for the organs showing the highest concentrations of chlorhexidine are summarised in the following Table. In all species, the concentration of chlorhexidine was dose-dependent and the effect was more pronounced in dogs than in rats. The most marked increase is seen in the liver of dogs. Species-specific differences are evident when the concentration of chlorhexidine in this organ is compared between dogs and rats. These toxicokinetic differences are reflected by differences in the target organ toxicity between both species.
Concentration of chlorhexidine in blood and organs of various
species after repeated oral or dermal
administration of chlorhexidine digluconate
Species |
Exposure duration, route, dose (mg chlorhexidine/kg · d) |
Chlorhexidine content (µg/g wet weight) |
|||
Blood |
Mesenteric lymph node |
Kidney |
Liver |
||
Dog |
1 a, oral (bolus), 0.5 |
n.d. |
~ 0.6 |
~ 3 |
~ 2 |
1 a, oral (bolus), 5 |
n.d. |
~ 4 |
~ 50 |
~ 60 |
|
1 a, oral (bolus), 40/25* |
0.1 ± 0.04 |
~ 93 |
~ 300 |
~ 600 |
|
Rat |
2 a, oral (drinking water), 5 |
not detectable |
6.7±6.0 |
11.9±4.7 |
0.24±0.11 |
2 a, oral (drinking water), 25 |
0.09±0.09 |
26.5±30.6 |
51.0±19.9 |
0.84±0.53 |
|
2 a, oral (drinking water), 50 |
0.26 ± 0.14 |
48.2 ± 36.3 |
124.2 ± 83.6 |
1.81 ± 1.08 |
|
2 a, oral (food), 5 |
0.06 + 0.03 |
22.5 ± 2.3 |
9.8 ± 0.9 |
0.12 ± 0.05 |
|
2 a, oral (food), 25 |
0.47 ± 0.06 |
39.5 ± 5.7 |
27.2 ± 4.1 |
0.70 ± 0.09 |
|
2 a, oral (food), 50 |
0.83 ± 0.07 |
43.7 ± 6.3 |
37.1 ± 4.8 |
0.73 ± 0.08 |
|
Mouse |
52 weeks, oral (food), 100 |
n.d. |
n.d. |
22 ± 3 |
n.d. |
65 weeks, oral (food), 100 |
n.d. |
n.d. |
62 ± 6 |
n.d. |
|
52 weeks, oral (food), 200 |
n.d. |
n.d. |
83 ± 3 |
n.d. |
|
65 weeks, oral (food), 200 |
n.d. |
n.d. |
169 ± 21 |
n.d. |
|
52 weeks, oral (food), 400 |
n.d. |
n.d. |
229 ± 8 |
n.d. |
|
65 weeks, oral (food), 400 |
n.d. |
n.d. |
388 ± 27 |
n.d. |
|
Rhesus monkey |
13 weeks, dermal (5 min wash), 400 |
0- 0.0111 |
n.d. |
0.018-0.044 |
0-0.0171 |
Humans |
3 weeks, 5 d/week, 5 times/d, dermal, 2x5 ml 4 % (2x3 min wash) |
not detectable2 |
n.d. |
n.d. |
n.d. |
*: dose reduction after 28 weeks; n.d.: not determined; 1:
chlorhexidine could be detected only in 1 of 6 animals;
2: limit of detection (LOD) in the order of 0.01-0.05 µg/ml. 3: LOD
3 ng/ml.
Few data are available concerning the metabolism of chlorhexidine digluconate. Para-chloroaniline (pCA), a known chemical breakdown product of chlorhexidine (may be present in concentrations up to 500 ppm as an impurity in the marketed chlorhexidine digluconate), is known to be rapidly excreted via urine after oral uptake. The substance could not be detected in urine samples from mouse, dog, rat, marmoset and humans following oral administration of 14C-labelled chlorhexidine. Further data show that ring- and chain 14C-labelled chlorhexidine produced the same metabolic pattern with respect to excretion in urine and faeces, indicating that cleavage of the molecule seems to be minimal. Analysis of faeces extracts from orally dosed animals revealed only chlorhexidine.
In summary, the available data indicate that the small amounts of chlorhexidine which may be absorbed following oral administration are not metabolised to a measurable extent.
Dermal route
Detailed information concerning excretion after dermal exposure to chlorhexidine digluconate is summarised in the following Table. While in rats some absorption was found, all studies with humans showed only very low absorption. Only in one study minor amounts could be detected in faeces. In 1 of 2 subjects treated with aqueous solution and in 1 of 3 subjects treated with hand wash solutions detectable levels were found in faeces (LOD: 0.006 % of the dose). In urine the detection limit is higher than in faeces; therefore, a reliable estimation of the amounts absorbed is not possible. If one assumes as for the oral studies, that similar amounts will be excreted in urine and in faeces, than dermal absorption in humans will amount to a maximum of about 0.2 % of the dose under different exposure conditions.
Excretion of14C-radioactivity
(as % of dose ± SE) following dermal administration
of14C‑chlorhexidine
digluconate to different species
Species |
Chlorhexidine solution |
Radio-label |
Exposure condition |
Urine |
Faeces |
Days |
Rat |
0.04 % |
C |
intact skin |
|
|
7 |
|
|
|
damaged skin |
0.3 |
3.5 |
|
Humans |
50 cm² |
|
5 % |
< 0.02 |
< 0.009 |
10 |
|
|
4 % |
< 0.02 |
< 0.009 |
10 |
|
|
1.4 aqueous dilution of skin cleanser |
|
|
< 0.1 |
n.d. |
1 |
|
Hand scrubbing 3 min with 5 ml 5x /day, 5 days/week, 3 weeks |
|
|
Not detectable |
Not detectable |
|
Additional data (summary of dermal uptake of chlorhexidine without specifying the chlorhexidine salt) are reported by EMEA (Committee for Veterinary Medicinal Products). No chlorhexidine could be detected in blood of neonatal Rhesus monkeys (except for one animal), which were bathed for 90 days in a cleanser containing 8 % chlorhexidine digluconate, and only trace amounts of chlorhexidine could be detected in fat, kidney, liver. Only the skin showed an appreciable amount of chlorhexidine, while no chlorhexidine could be detected in bile. In humans, no chlorhexidine could be detected in the blood of infants washed in a 4 % chlorhexidine solution. Similarly, chlorhexidine could not be detected in the blood of adults after a single topical application of a 5 % solution of 14C- labelled chlorhexidine to 50 cm² skin (LOD for blood: 0.005 µg/ml [0.02 % of applied dose]) or after repeated daily use in a pre-operative “scrub” over a period of 6 months (LOD for blood: 0.01 µg/ml).
Some additional information may be gathered from a comparison of the acute lethal toxicity of chlorhexidine for different routes of administration. The acute LD50 for i.v. administration is about two orders of magnitude lower than the LD50 for oral and the ratio is even higher for the (non-lethal) concentrations applied to the skin. This large differences in acute lethal toxicity between a route where the substance directly enters the body and routes where absorption through the gastrointestinal tract or the skin is necessary to elicit systemic toxic effects further supports the conclusion that oral and – even more – dermal absorption of chlorhexidine is low.
Conclusion
Chlorhexidine – as is expected because of its cationic nature – is strongly bound to mucosa and skin. The chlorhexidine content in the organs of animals after repeated oral administration show that some chlorhexidine is absorbed from the gastrointestinal tract. Kinetic studies indicate that the oral absorption is low (ca. 2 % of the dose, based on data of urinary and biliary excretion).
Dermal absorption is very low and considerably lower than oral absorption. Experimental data for humans show that uptake is too low to be measurable even with 14C-labelled chlorhexidine. Taking into account the limit of detection, a value of 0.02 % is considered as an upper bound estimate for percutaneous absorption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.